English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessMoneycontrol ResearchSun Pharma: Traction in speciality likely to sustain

    Sun Pharma: Traction in speciality likely to sustain

    Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well

    Anubhav Sahu
    May 31, 2021 / 10:53 IST
    Sun Pharma: Traction in speciality likely to sustain

    Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.

    • PRO Panorama

      Moneycontrol Pro Panorama | Capital craze

      Sep 29, 2025 / 02:48 PM IST

      In Moneycontrol Pro Panorama September 29 edition: Trump's pharma tariff drives markets lower, steel sector at crossroads, recruit...

      Read Now
    • PRO Weekender

      Moneycontrol Pro Weekender | When the Ground Shifts

      Sep 27, 2025 / 10:00 AM IST

      In a week where the fault lines of markets, technology, and policy all seemed to move at once, the only certainty is that change i...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts

    Disclosure & Disclaimer

    This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More